

PET – A new method to see the function of the brain

National /Turku PET Centre

at night

Staff > 100 3 cyclotrons 3 PET-scanners PET/CT scanner (64 slice CT) 1.5T MRI A Joint National Research Institute of University of Turku, Åbo Akademi University and Turku University Central Hospital

http://www.turkupetcentre.fi

Mika Teräs SAT2006 Helsinki 8.9.2006

PET – A new method to see the function of the brain

- Basic physics of PET method
- PET in neuro research and drug development
- Present and future trends in neuroPET

What is **PET**?

- PET= Positron Emission Tomography
- A computerized tomography employing short lived (2 min - 2 hour) radioactive isotopes (¹¹C, ¹³N, ¹⁵O, ¹⁸F, ⁶⁸Ga)
- Enables noninvasive study of tissue molecular function





Common Positron Emitters

- $14N(p,\alpha)^{11}C$ $T_{\frac{1}{2}} = 20.4$ min
- $\overline{{}^{16}O(p,\alpha)}{}^{13}N$ $T_{\frac{1}{2}} = 10.0$ min
- $^{14}N(d,n)^{15}O$ $T_{\frac{1}{2}} = 2.05 \text{ min}$
- ${}^{18}O(p,n){}^{18}F$ $T_{\frac{1}{2}} = 109.8 \text{ min}$

Need a cyclotron !





LOR (Line Of Response) is a line (or tube) between two opposing crystals. Tube diameter is angle dependent.

Turku PET Centre

represented by one diamond



3D PET

no septa

→4 times better sensitivity

Axial plane difference Is defined by number of segments. Segment 0 represents 2D image



Analysis of PET Results (1)

1) Absolute quantification

- Draw ROIs on MRI images
- Mathematical modeling
- Blood samples usually needed



2) 3D mapping of relative changes

Statistical parametric mapping (SPM)



Analysis of PET Results (2)

2)Tissue

activity

Modelling

- 1) on-line arterial activity
 2) dynamic 3D PET data
 3) metabolite samples
- => Model => Quantitative result

1)Arterial activity







- = blood flow i = arterial concentration of tracer = tissue concentration of tracer = distribution volume of tracer
- = amount of tracer / g of tissue amount of tracer / ml of blood



PET – A new method to see the function of the brain

- Basic physics of PET method
- PET in neuro research and drug development
- Present and future trends in neuroPET

The Role of PET in Brain Imaging



Advantages of PET in neurotransmitter studies

- PET is one of the few tools enabling investigation on neurotransmission in living human brain
- Wide selection of radiopharmaceuticals
- "Biological" radiopharmaceuticals
- Quantitation

PET in neurotransmitter research: dopaminergic synapse



Activation studies

- PET imaging during "baseline" and "task"
- "Activation" = "task" "baseline"
- "Activation" is considered to represent increased neuronal function in brain areas involved in the task

Glucose metabolism



Visuospatial representations used by chess experts: A preliminary study

Pertti Saariluoma Computer and Information Sciences, University of Jyväskylä, Finland

Hasse Karlsson Department of Psychiatry, University of Helsinki, and PET Centre, University Central Hospital of Turku, Finland

> Heikki Lyytinen Department of Psychology, University of Jyväskylä, Finland

Mika Teräs and Fabian Geisler PET Centre, University Central Hospital of Turku, Finland

Blindfold chess is played without the players seeing either the pieces or the board. It is a skill-related activity, and only very skilled players can construct the mental images required. This is why blindfold chess provides a good task with which to investigate the spatial memory and skilled mental images of expert players. In a PET investigation, we compared memory performance and problem solving in very experienced chess players with their performance in an attention task, in which the subjects classified the names of chess pieces. The memory task predominantly activated the temporal areas, whereas problem solving activated several frontal areas. The relevance of these findings to concepts such as general imagery, skilled imagery, apperception, and long-term working memory are discussed.

Correspondence should be addressed to Perti Saarihoona, Computer and Information Sciences, University of Jyväskylä, Box 35, Jyväskylä, Finland. Email: psa@it.jyu.fi

This work was funded by the University of Helsinki for the first author, and by the Turka PET Centre. We would like to thank Steven Crawford for correcting the English. We also thank Michel Denis and two anonymous reviewers for very detailed and constructive comments.

© 2004 Psychology Press Ltd http://www.tandf.co.uk/journals/pp/09541446.html DOI:10.1080/09541440340000501

















Figure 1. Brain regions associated with blindfold chess. (a) Memory – Attention; (b) Problem solving – Attention; (c) Problem solving – Memory.

Activation studies: cortical dopaminergic system

• [¹¹C] FLB 457

- high affinity D_2 / D_3 antagonist
- reversible binding
- enables visualisation of cortical and extrastriatal dopamine receptors
- competition with endogenous dopamine
 → Dopamine ↑ → [¹¹C]-FLB ↓
 → Dopamine ↓ → [¹¹C]-FLB ↑

[11C]FLB, a reversibly binding high affinity dopamine D2 receptor antagonist

Calculated binding potential images





Activation studies: cortical dopaminergic system

• Tasks

- baseline
- 0-back ("vigilance")
- 2-back ("working memory")
- single consonants were presented visually by a PC on a projector screen



Activation studies: cortical dopaminergic system



WM - vigilance

PET in brain diseases

- Diagnosis / differential diagnosis
- Follow-up
- Detection of asymptomatic cases
- Development of treatment
- Monitoring of treatment effects
 - drug treatment
 - lesions
 - stimulations
 - transplantation
 - gene teraphy
 - other teraphies

Organisation of Nigrostriatal dopamine interconnections

Pathophysiology of PD Loss of dopaminergic neurons in the substantia nigra leading to dopamine deficiency in the basal ganglia



Degree of cell destruction

¹⁸F-dopa PET: twin study







Control

Healthy sibling of a monozygotic PD patient Same person 5 years later, symptomatic

Differential Diagnosis of Dementia



Receptor occupancy studies with PET – implications for drug development

- 'Proof of concept'
- Enhancement of dose-finding procedures for further drug development
- Critical issues: Imaging methodology development and timing of PET studies in order to get maximal benefit



"Optimal" properties for a PET radiotracer for brain

- Unfortunately, no absolute criteria ! Good drug ≠ good tracer
- Suitable for high specific radioactivity labelling (usually 11C or 18F)
- selective and specific ligand, affinity high but not too high (equilibrium within the scan time) – fast plasma clearance helps
- no radioactive metabolites entering the brain
- free fraction in plasma should be measurable (helps modelling)
- not toxic, appropriate radiation dosimetry
- Optimal lipophilicity; Log P < 3.5 but not too low as non-specific binding may increase limiting access to CNS (plasma proteins, lungs, liver, spleen)

D₂ receptor occupancy (%)



Modified from Syvälahti and Hietala 1998 **Dose (units)** Turku PET Centre

Dopamine D₂ receptor occupancy





Nordström A-L 1993

Haloperidol

Occupancy of µ-Opioid Receptors by Nalmefene

^{[11}C]Carfentanil

BP before administration



Ingman et al, 2005

NK1 receptor occupancy by a NK1 receptor antagonist, aprepitant



Aprepitant 100 mg, 2 weeks

Bergström M, *Hargreaves RJ, *Burns HD, *Goldberg MR, *Sciberras D, *Reines SA, *Petty KJ, *Ögren M, *Antoni G, *Långström B, Eskola O, Scheinin M, Solin O, *Majumdar AK, *Constanzer ML, *Battisti WP, *Brandstreet TE, *Gargano C, Hietala J. (Biol Psy, 55:1007-1012, 2004)

Conclusions

PET is a versatile method to study the role of neurotransmitter systems in
Normal brain functions
Brain diseases
Drug development

but, keep in mind that

PET has poor temporal resolution

Auditory hallucinations in schizophrenia – fMRI study



PET – A new method to see the function of the brain

- Basic physics of PET method
- PET in neuro research and drug development
- Present and future trends in neuroPET



Micro PET

Effect of resolution





Resolution

2mm

1mm

Image courtesy of The University of Tennessee Medical Center

30g Mouse Focus™ 120



4mm





The effect of reconstruction method

ICTOPI

÷.

...

7

Ú.

D T

2e



FOCUS

a new perspective

A miniature Derenzo phantom was filled with an "F solution and scanned in the microPET* Focus_{me}. The diameter of the rods was 2.5 mm, 2.0 mm, 1.5 mm, 1.25 mm, 1.0 mm, and 0.8 mm, respectively. Center-to-center distance between adjacent rods was 2 times the rod diameter. Below is the resulting data processed with Filter Back Projection, 2D-OSEM, and MAP. In all three images the Focus_{me} system resolved the 1.25 mm diameter rods nicely and is showing promise in identifying the 1.0mm rods using MAP.



Miniature Derenzo phantom

2.5mm 2.0mm 0.0mm 1.5mm 1.5mm 1.25mm 1.25mm 1.25mm 1.25mm 1.25mm 1.25mm 1.25mm 1.25mm 1.25mm 1.25mm

Monkey brain phantom

The Block detector a LSO/ LYSO detector



coinc_eff(lso/lyso, 2 cm) = 1.23 *coinc_eff(lso/gso, 1.5 cm) Total of 59 904 LSO and LYSO elements

HRRT

- High Resolution Research Tomograph
- High resolution (2.5 3 mm)
- 47-cm panel separation
- 25-cm axial FOV
- High sensitivity (5-6%)
- Phoswich detectors (LSO/LYSO 2x2x10 mm)
- List mode
- 119,808 crystals
- 4.5x10⁹ LORs





Comparison of PET scanners from different generations

	ECAT 931	GE Advanc	e HRRT	HRRT	
	2D	(2D /) 3D	only 3D		
Year of purchase	1988	1996	2003?		
Number of rings	8	18	104		
Slice Thickness (mm)	6,75	4,25	1,2		
Crystal material	BGO	BGO	LSO/LYSO		
Crystal size (mm)	5,6x12,5x30	4x8x30	2x(2,1x2,1x1	0)	
Number of crystals	4096	12096	119808		
Axial length (cm)	10	15	25		
Patient port diameter (cm)	62	60	35		
Spatial resolution (mm)	6	4	2,5		
Sensitivity (kcps/uCi/ml)	100	1200	n. 2500		
Size of a raw data frame (Mb)	2	50	326		
Frame reconstruction time (min)	1	4	200, 30 w ith clu	uster	

The second generation HRRT – a multi-centre scanner performance investigation

V. Sossi¹, H. W. A. M. de Jong², W. C. Barker³, P. Bloomfield⁴, Z. Burbar⁵, M.-L. Camborde⁶, R. E. Carson⁷, C. Comtat⁸, L. A. Eriksson⁵, S. Houle⁴, D. Keator⁹, C. Knöß¹⁰, R. Krais¹¹, A. A. Lammertsma², A. Rahmim¹², M. Sibomana⁵, M. Teräs¹¹, C. J. Thompson¹³, R. Trébossen⁸, J. Votaw¹⁴, K. Wienhard¹⁰, D. F. Wong¹²

¹Physics and Astronomy, University of British Columbia, Vancouver, Canada, ²VU University Medical Center, Amsterdam, The Netherlands, ³NIH Clinical Center, Bethesda, USA, ⁴CAMH, Toronto, Canada ³Siemens Medical Systems, Knoxville, USA, ⁶PPRC, University of British Columbia, Vancouver, Canada, ⁷Yale University New Haven, New Haven, USA, ⁸Frédéric Joliot Hospital Facility, CEA/DSV, Orsay, France ⁹Psychiatry & Human Behavior, University of California, Irvine, USA, ¹⁰Max Planck Institute for Neurological Research, Cologne, Germany, ¹¹Turku PET Centre, Turku, Finland, ¹²Radiology, The Johns Hopkins University School of Medicine, Baltimore, USA, ¹³Montreal Neurological Institute, McGill University, Montreal, Canada, ⁴⁴Radiology and Physics, Emory University, Atlanta, USA

ABSTRACT

The high resolution research tomograph (HRRT-CTI PET Systems) is one of the most complex existing PET scanners: [1,2,3] it is the only human size scanner capable of decoding the depth of the gamma ray interaction (DOI) in the crystal, using an LSO/LYSO phoswitch detector arrangement, leading to a total of 119,808 detector crystals. In this study we determined basic scanner hardware characteristics, such as scanner data acquisition stability, and their variability across 11 centers. In addition a subset of the NEMA NU-2001 standards measurements was performed. We found (i) significant variability in the DOI decoding results between centers, (ii) a trend toward an increasing number of detected true coincident events as a function of elapsed time from scanner calibration likely due to a shifting energy spectrum, (iii) a count rate dependent layer identification (iv) scatter fraction ranging from ~42% to 54% where the variability was equally related to the shifting of the nergy spectrum, (v) sensitivity ranging from ~5.5% to 6.5% across centers, (vi) resolution of ~(2.5mm)⁴, fairly consistent across centers, (vi) image quality give results very comparable to other scanners.

INTRODUCTION

The high resolution research tomograph (HRRT -CTI PET Systems - fig. 1) is one of the most complex existing PET scanners: it is the only human size scanner capable of decoding the depth of the gamma ray interaction (DOI) in the crystal. DOI determination is achieved by means of a phoswitch detector utilizing crystals (Fig.2) with different decay times and subsequent pulse shape discrimination [4]: the first layer is LSO and the second layer is LYSO (Lu0.6Y1.4SiO5:Ce, i.e. 70 % YSO and 30 % LSO). The decay time of LSO is approximately 43-44 nsec, while that of LYSO is approximately 53 nsec.[5,3]

IEEE-MIC 2005



Figure & HRRT: 25 cm axial FOV 8 planar detectors 119,808 crystals 25 cm axial FOV 30 cm radial FOV



Figure 2 Detector block: 128 2 2x2 2x10 mm³ crystals 2 44 mm average crystal pitch

The ability to correctly identify the gamma interaction in each layer depends on several factors:

- the actual decay time separation between crystals,
- the accurate calibration of the photomultiplier tube gains
- timing alignment between signals coming from different crystals
- the count-rate to which the crystals are exposed during data acquisition
- stability of the hardware components over time

Each of these aspects is prone to some uncortainty and variability, for example:

- . the crystal manufacturing process does not consistently produce LSO and LYSO with exactly the same decay time,
- the detector set-up procedure is extremely complex, time consuming and requires manual intervention thus introducing some degree of operator dependency
- hardware can be influenced by aging and radiation exposure.

Resolution Comparison

Commercial PET-CT





HRRT



Fig. 7. Distribution of [F-18]SPA-RQ uptake in the midbrain-pons-medulla of a healthy male volunteer. Sagittal slice of an integrated image from 190 to 240 min is aligned with the structural MR image from the same subject. There is moderate uptake in the superior and inferior colliculi of the midbrain as well as in the nuclei group in medulla (e.g., nucleus solitaris, nucleus ambigus, and other nuclei of vagus, trigeminal nucleus, inferior salivary nucleus, and area postrema). In addition, there is some uptake in the pons representing tegmentum and possibly raphe nuclei. Because of limitations in resolution, these locations are tentative. Note also the high [¹⁸F]SPA-RQ binding in ventral striatum and cortex, moderate binding in thalamic nuclei, and very low cerebellar uptake in this slice.

GE Advance PET camera

et al MIB 2005 Turku PET Centre

High resolution PET and NK1 receptors, [¹⁸F]SPA-RQ and ECAT HRRT

Need for improved image processing and automated advanced image analysis techniques



MOLAR

- Motion-compensation OSEM List-mode Algorithm for Resolution-recovery reconstruction
- All physical effects in the system model
- Exact LOR positioning
- Event-by-event motion correction (Polaris)
- System matrix computed on-the-fly
- LOR-based line spread functions
- Randoms estimation from singles
- Single scatter simulation model
- Component-based count-rate dependent normalization
- 256x256x207 images (1.2 mm/voxel)





Multiparametric Image Fusion Algorithms -

Z.H. Cho et.al. Neuroscience Research Institute, Gachon Medical University, Incheon, Korea







PET-MRI What is it ?

Max Planck Institute for Neurological Research



MAX-PLANCK-GESELLSCHAFT

with Klaus-Joachim-Zülch-Laboratories of the Max Planck Society and the Faculty of Medicine of the University of Cologne, Director Prof. Dr. D. Yves on Cramon

> The Max Planck Inst 200° for Neurological P1, 200° for invites applice of 1, for four Group I - Appositions - Chaindige - Chai

Currently, the following technologies / methods are available at the Institute: human brain PET (EXACT-HR, HRRT), animal PET (µPET) and animal MRI (4.7T, 7.0T, 11.7T), optical imaging (bioluminescence, fluorescence and laser scanning microscopy) autoradiography, electron microscopy, histology, immunohistochemistry and invasive imaging / neuromonitoring (microdialysis, subdural EEG). In 2006, a combined human brain PET-MR-System will be installed.

Thank you !

This review was done in collaboration with

- Professor Jarmo Hietala, Psychiatry
- Professor Juha Rinne, Neurology
- Professor Harry Scheinin, Drug development